middle.news
PainChek FDA Clearance Unlocks $3B US Market with $5.6M ARR SaaS Model
9:15am on Friday 30th of January, 2026 AEDT
•
Healthcare
Read Story
PainChek FDA Clearance Unlocks $3B US Market with $5.6M ARR SaaS Model
9:15am on Friday 30th of January, 2026 AEDT
Key Points
FDA De Novo clearance achieved October 2025
$5.6M contracted ARR with $4.0M implemented ARR as of January 2026
17 million pain assessments conducted globally across 1900+ aged care homes
Access to US Medicare reimbursement via Remote Therapeutic Monitoring (RTM) codes
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PAINCHEK (ASX:PCK)
OPEN ARTICLE